Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.

@article{Sterkers1998AcuteML,
  title={Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.},
  author={Y. Sterkers and C. Preudhomme and Jean-Luc La{\"i} and Jean-Loup Demory and M. Caulier and E. Wattel and D. Bordessoule and F. Bauters and P. Fenaux},
  journal={Blood},
  year={1998},
  volume={91},
  pages={616-622}
}
  • Y. Sterkers, C. Preudhomme, +6 authors P. Fenaux
  • Published 1998
  • Medicine
  • Blood
  • Treatment with alkylating agents or radiophosphorous (32P) has been shown to carry a certain leukemogenic risk in myeloproliferative disorders (MPDs), including essential thrombocytemia (ET). The leukemogenic risk associated to treatment with hydroxyurea in ET, on the other hand, is generally considered to be relatively low. Between 1970 and 1991, we diagnosed ET in 357 patients, who were monitored until 1996. One or several therapeutic agents had been administered to 326 patients, including… CONTINUE READING
    12 Citations
    Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long‐term follow‐up of a randomized clinical trial
    • 195
    • Highly Influenced
    How I treat patients with polycythemia vera.
    • 121
    • PDF
    Emerging drugs for essential thrombocythemia

    References

    SHOWING 1-10 OF 61 REFERENCES